Short Interest in Ironwood Pharmaceuticals, Inc. (IRWD) Grows By 7.6%
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was the target of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 20,725,777 shares, an increase of 7.6% from the February 15th total of 19,260,215 shares. Currently, 16.4% of the shares of the company are short sold. Based on an average daily trading volume, of 1,336,290 shares, the short-interest ratio is currently 15.5 days.
Ironwood Pharmaceuticals (NASDAQ IRWD) opened at $15.25 on Friday. The company has a debt-to-equity ratio of 40.25, a quick ratio of 4.71 and a current ratio of 4.72. Ironwood Pharmaceuticals has a 12-month low of $12.89 and a 12-month high of $19.94. The firm has a market cap of $2,320.00, a price-to-earnings ratio of -19.30 and a beta of 1.27.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, February 15th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.04. Ironwood Pharmaceuticals had a negative net margin of 39.20% and a negative return on equity of 2,073.20%. The firm had revenue of $94.20 million during the quarter, compared to analyst estimates of $88.86 million. During the same quarter in the prior year, the business earned ($0.12) earnings per share. Ironwood Pharmaceuticals’s revenue for the quarter was up 7.7% on a year-over-year basis. analysts expect that Ironwood Pharmaceuticals will post -0.46 EPS for the current year.
In other Ironwood Pharmaceuticals news, CFO Gina Consylman sold 3,594 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $14.66, for a total value of $52,688.04. Following the completion of the transaction, the chief financial officer now directly owns 59,125 shares in the company, valued at $866,772.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Mark G. Currie sold 60,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $15.45, for a total transaction of $927,000.00. Following the completion of the transaction, the insider now owns 835,000 shares of the company’s stock, valued at $12,900,750. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 66,728 shares of company stock valued at $1,024,732. 7.63% of the stock is owned by corporate insiders.
Several large investors have recently modified their holdings of the stock. Xact Kapitalforvaltning AB bought a new position in shares of Ironwood Pharmaceuticals during the fourth quarter worth $220,000. MetLife Investment Advisors LLC bought a new position in shares of Ironwood Pharmaceuticals during the fourth quarter worth $955,000. Park West Asset Management LLC bought a new position in shares of Ironwood Pharmaceuticals during the fourth quarter worth $9,203,000. Millennium Management LLC bought a new position in shares of Ironwood Pharmaceuticals during the fourth quarter worth $367,000. Finally, Sarissa Capital Management LP bought a new position in shares of Ironwood Pharmaceuticals during the fourth quarter worth $24,733,000.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.